Growth Metrics

Core Laboratories (CLB) Long-Term Deferred Tax (2022 - 2026)

Core Laboratories filings provide 5 years of Long-Term Deferred Tax readings, the most recent being $71.3 million for Q1 2026.

  • On a quarterly basis, Long-Term Deferred Tax rose 5.55% to $71.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $71.3 million, a 5.55% increase, with the full-year FY2025 number at $67.4 million, down 3.21% from a year prior.
  • Long-Term Deferred Tax hit $71.3 million in Q1 2026 for Core Laboratories, up from $67.4 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $72.3 million in Q3 2023 to a low of $66.3 million in Q1 2024.
  • Median Long-Term Deferred Tax over the past 5 years was $69.6 million (2024), compared with a mean of $69.4 million.
  • Biggest five-year swings in Long-Term Deferred Tax: dropped 3.29% in 2024 and later rose 5.55% in 2026.
  • Core Laboratories' Long-Term Deferred Tax stood at $68.6 million in 2022, then rose by 0.92% to $69.2 million in 2023, then grew by 0.6% to $69.6 million in 2024, then dropped by 3.21% to $67.4 million in 2025, then increased by 5.81% to $71.3 million in 2026.
  • The last three reported values for Long-Term Deferred Tax were $71.3 million (Q1 2026), $67.4 million (Q4 2025), and $70.5 million (Q3 2025) per Business Quant data.